Multiple Sclerosis-Drug Pipeline Analysis and Market Forecasts to 2015

Oct. 8, 2010 - PRLog -- "Multiple Sclerosis-Drug Pipeline Analysis and Market Forecasts to 2015". The report is an essential source of information and analysis on the global multiple sclerosis (MS) market. The report identifies the key trends shaping and driving the global MS market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global MS sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Scope
The scope of the report includes:  
-Annualized global multiple sclerosis market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
-Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
-Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action include immunomodulator and anti-inflammatory, cytokine and cytokine-receptor targetters, ion channel targetters, metabolic pathway's enzymes targetters, remyelination stimulator and demyelination inhibitor, and neurotransmitters targetters.
-Analysis of the current and future market competition in the global multiple sclerosis market. Key market players covered are Biogen idec, Merck Serono, Sanofi Aventis, AstraZeneca and Glenmark Pharmaceuticals Ltd.
-Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
-Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with multiple sclerosis.

Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
-Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
-Develop business strategies by understanding the trends shaping and driving the global multiple sclerosis market.
-Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global multiple sclerosis market in future.
-Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
-Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
-What's the next big thing in the global multiple sclerosis market landscape? -Identify, understand and capitalize.



Table of Contents
1 Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Market Characterization 6
2.1 Overview 6
2.2 Multiple Sclerosis Market Size 6
2.3 Multiple Sclerosis Market Forecast and CAGR 6
2.4 Drivers and Barriers for Multiple Sclerosis Market 7
2.4.1 Drivers for Multiple Sclerosis Market 7
2.4.2 Barriers for Multiple Sclerosis Market 7
2.5 Opportunity and Unmet Need 8
2.6 Key Takeaway 9
3 Competitive Assessment 10
3.1 Overview 10
3.2 Strategic Competitor Assessment 10
3.3 Product Profile for the Major Marketed Products in Multiple Sclerosis Market 11
3.3.1 Copaxone (Glatiramer Acetate) 11
3.3.2 Avonex/Rebif (Interferon Beta) 12
3.3.3 Tysabri (Natalizumab) 13
3.3.4 Novantrone (Mitoxantrone) 14
3.3.5 Betaseron/Betaferon 15
3.4 Key Takeaway 17
4 Pipeline Assessment 19
4.1 Overview 19
4.2 Strategic Pipeline Assessment 19
4.2.1 Technology Trends Analytic Framework 19
4.3 Multiple Sclerosis Therapeutics-Promising Drugs under Clinical Development 21
4.4 Molecule Profile for Promising Drugs under Clinical Development for Multiple Sclerosis 22
4.4.1 Mylinax (Cladribine Oral Formulation) 22
4.4.2 Teriflunomide 23
4.4.3 BG-12 23
4.4.4 Fingolimod 24
4.4.5 Laquinimod 24
4.5 Multiple Sclerosis Therapeutics Market-Clinical Pipeline by Mechanism of Action 25
4.6 Multiple Sclerosis Pipeline-Pipeline by Clinical Phases of Development 26
4.6.1 Multiple Sclerosis Therapeutics-Regulatory and Phase III Clinical Pipeline 26
4.6.2 Multiple Sclerosis Therapeutics-Phase II Clinical Pipeline 27
4.6.3 Multiple Sclerosis Therapeutics-Phase I Clinical Pipeline 29
4.6.4 Multiple Sclerosis Therapeutics-Pre-Clinical Pipeline 30
4.6.5 Multiple Sclerosis Therapeutics-Discovery Pipeline 32
4.7 Discontinued/Suspended Drugs for Multiple Sclerosis 32
4.8 Key Takeaway 33
5 Multiple Sclerosis Market: Implications for Future Market Competition 34
6 Multiple Sclerosis Market: Future Players in Multiple Sclerosis Market 35
6.1 Introduction 35
6.2 Biogen idec 35
6.2.1 Overview 35
6.2.2 CNS Portfolio 36
6.2.3 Multiple Sclerosis Product Portfolio 36
6.3 Merck Serono 37
6.3.1 Overview 37
6.3.2 CNS Portfolio 37
6.3.3 Multiple Sclerosis Product Portfolio 38
6.4 Sanofi-aventis 39
6.4.1 Overview 39
6.4.2 CNS Portfolio 39
6.4.3 Multiple Sclerosis Product Portfolio 39
6.5 AstraZeneca 40
6.5.1 Overview 40
6.5.2 CNS Portfolio 40
6.5.3 Multiple Sclerosis Product Portfolio 41
6.6 Glenmark 41
6.6.1 CNS Portfolio 42
6.6.2 Multiple Sclerosis Product Portfolio 42
7 Multiple Sclerosis Market: Appendix 43
7.1 Definitions 43
7.2 Acronyms 43
7.3 Research Methodology 43
7.3.1 Coverage 44
7.3.2 Secondary Research 44
7.3.3 Forecasting 45
7.3.4 Primary Research 47
7.3.5 Expert Panels Validation 48
7.4 Contact Us 48
7.5 Disclaimer 48
7.6 Sources 48

List of Tables
1.1 List of Tables
Table 1: Global Multiple Sclerosis Therapeutics Market, Revenue ($m), 2000-2015 7
Table 2: Global Multiple Sclerosis Therapeutics Market, Revenue ($m), 2000-2015 7
Table 3: Major Marketed Products Comparison in Multiple Sclerosis Market,  2009 17
Table 4: Multiple Sclerosis Therapeutics-Most Promising Drugs Under Clinical Development, 2009 21
Table 5: Multiple Sclerosis Therapeutics-Regulatory and Phase III Clinical Pipeline, 2009 26
Table 6: Multiple Sclerosis Therapeutics-Regulatory and Phase III Clinical Pipeline (Contd..), 2009 27
Table 7: Multiple Sclerosis Therapeutics-Phase II Clinical Pipeline, 2009 27
Table 8: Multiple Sclerosis Therapeutics-Phase II Clinical Pipeline (Contd..), 2009 28
Table 9: Multiple Sclerosis Therapeutics-Phase II Clinical Pipeline (Contd..), 2009 29
Table 10: Multiple Sclerosis Therapeutics-Phase I Clinical Pipeline, 2009 29
......

List of Figures
1.2 List of Figures
Figure 1: Global Multiple Sclerosis Market, Revenue ($m), 2000-2015 6
Figure 2: Opportunity and Unmet Need in the Multiple Sclerosis Market, 2009 9
Figure 3: Strategic Competitor Assessment of the Major Marketed Products in Multiple Sclerosis, 2009 11
Figure 4: Technology Trends Analytic Framework for the Multiple Sclerosis Pipeline, 2009 20
Figure 5: Technology Trends Analytic Framework of the Multiple Sclerosis Pipeline-Description, 2009 20
......

# # #

ChinaCCM.com is China's leading industry consultancy expert offering industry intelligence and research solution, ChinaCCM Market Research Centre is a research division focusing on professional market survey and industry research.